Showing 1 - 10 of 48
Drug Policy of 1986
Persistent link: https://www.econbiz.de/10009323735
The Drug Policy, 1994 needed to be revised to  meet  the  challenges  brought  about  by  the  competitive  international  pharmaceutical  industry  in  a  globalised  economic  environment,  as...
Persistent link: https://www.econbiz.de/10009358535
Modifications to Drug Policy 1986
Persistent link: https://www.econbiz.de/10009250151
Pharmaceutical Policy of 2002 covering issues of pricing, ,marketing, size of market, quality, production, investment, regulatory authority, monitoring, ethical issues
Persistent link: https://www.econbiz.de/10009250530
THE DRUGS AND COSMETICS (AMENDMENT) BILL, 2005 A Bill further to amend the Drugs and Cosmetics Act, 1940. Under examination with the Committee on Health and Family Welfare On adulterated and spurious drugs
Persistent link: https://www.econbiz.de/10005528115
The Task Force recommends that price regulation should be on the basis of ‘Essentiality’ of the drug and it should … uniform price, and only a ceiling price should be indicated. The regulatory mechanism should be significantly strengthened … for price control on drugs. As a long term objective, the Task Force endorses the proposal made by the Planning Commission …
Persistent link: https://www.econbiz.de/10005528148
product patents for pharmaceuticals, this paper provides a rigorously-derived estimate of the possible impact of … pharmaceutical prices and sales over a two year period from January 1999 to December 2000, the study estimates key price and …-bacterials (i.e., antibiotics) in the Indian pharmaceuticals market. These estimates are then used to carry out counterfactual …
Persistent link: https://www.econbiz.de/10005528220
examination for pharmaceuticals inventions, particularly in developing countries. It proposes a set of general guidelines for the …
Persistent link: https://www.econbiz.de/10005528232
This report analyzes the ITRIPS agreement. It discuses the problems and stakes, and consequences of this agreement. The report also provides case studies related to the topic and finally gives a suggestive conclusion.
Persistent link: https://www.econbiz.de/10005528311
While welcoming the move to withdraw the Report of the Technical Expert Group on Patent Law Issues AIDAN has issued a statement that the group must not be allowed to re-submit the report. The matter must be referred to a Parliamentary Standing Committee.
Persistent link: https://www.econbiz.de/10005528317